Interpretation of the 5th edition of WHO classification of endocrine and neuroendocrine tumors: update and progress on follicular cell-derived thyroid tumors
Journal Title: Journal of Surgery : Concepts & Practice - Year 2025, Vol 30, Issue 1
Abstract
The 2022 WHO classification of endocrine and neuroendocrine tumors (5th edition) categorizes thyroid follicular cell-derived tumors into benign, low-risk, and malignant types. Benign tumors now include thyroid follicular nodular lesions. A newly added category previously termed "borderline tumors" have been revised to low-risk follicular cell-derived tumors, which encompass non-invasive follicular thyroid neoplasm with papillary-like nuclear features, thyroid tumors of uncertain malignant potential, and hyalinizing trabecular tumors. The new WHO classification stratifies malignant follicular cell-derived tumors based on molecular characteristics and invasiveness: papillary thyroid carcinoma (PTC) with various histological subtypes represents BRAF-like malignancies; invasive encapsulated follicular variant PTC and follicular thyroid carcinoma represent RAS-like malignancies. Oncocytic carcinoma is now recognized as a distinct entity, specifically referring to tumors composed of ≥75% oncocytic follicular cells lacking PTC nuclear features and high-grade characteristics (necrosis and mitotic figures ≥3/2 mm²). A new category termed "high-grade follicular cell-derived thyroid carcinoma" has been added, encompassing traditional poorly differentiated thyroid carcinoma and differentiated high-grade thyroid carcinoma. Anaplastic thyroid carcinoma(ATC) remains the most undifferentiated type, with thyroid squamous cell carcinoma now classified as a subtype of ATC. The term "papillary thyroid microcarcinoma" is no longer recommended as a distinct subtype. Cribriform-morular thyroid carcinoma is no longer classified as a subtype of PTC, but is instead categorized as a tumor of uncertain histogenesis.
Authors and Affiliations
Shanshan LU, Yuan JI
Keywords
Related Articles
- EP ID EP765824
- DOI 10.16139/j.1007-9610.2025.01.06
- Views 12
- Downloads 0
Predictive factors of pathological complete response after neoadjuvant therapy for locally advanced rectal cancer
[Objective] To analyze the tumor characteristics associated with achieving pathological complete response(pCR) and tumor prognosis in the patients undergoing laparoscopic rectal cancer surgery after neoadjuvant chemoradi...
Organ preservation strategies for rectal cancer treatment: tarts or trap?
Total mesorectal excision (TME) is the standard treatment for advanced mid- and low-rectal cancer. However, the associated surgical complications and subsequent impairment of organ function limit its application. In rece...
<![CDATA[Current status and development of laparoscopic hepatectomy]]>
<![CDATA[]]>
Influence of neoadjuvant radiotherapy combined with immunotherapy on minimally invasive surgeries for rectal cancer
The current domestic and international guidelines recommend neoadjuvant chemoradiation or total neoadjuvant therapy followed by radical surgery for mid-low locally advanced rectal cancer. In recent years, the significant...
Transanal total mesorectal excision in re-operation for anastomosis recurrence rectal cancer
[Objective] To investigate the feasibility and safety of transanal total mesorectal excision (TaTME) in re-operation for anastomosis recurrence rectal cancer. [Methods] Five patients with anastomosis recurrence rectal ca...